Zoll Banking On M-Series Superiority Claim In Entering Public AED Market
This article was originally published in The Gray Sheet
Executive Summary
Zoll Medical is expecting the smaller size of its biphasic M-Series automated external defibrillator (AED) combined with FDA-cleared superiority claims over competing devices to result in a sizable chunk of the public access defibrillator market.
You may also be interested in...
Zoll Defibrillator Sales Growth, Upcoming Public AED Entry Buoy Stock In July
Zoll Medical's upcoming entry into the public access automated external defibrillator (AED) market, coupled with revived sales growth in its third fiscal quarter, helped the firm's stock jump ahead 33% in July. The issue closed at $36.45, up $9 for the month.
Zoll Defibrillator Sales Growth, Upcoming Public AED Entry Buoy Stock In July
Zoll Medical's upcoming entry into the public access automated external defibrillator (AED) market, coupled with revived sales growth in its third fiscal quarter, helped the firm's stock jump ahead 33% in July. The issue closed at $36.45, up $9 for the month.
Zoll Biphasic Defibrillator Study Results Show Superiority In AF Treatment
Zoll Medical expects to begin shipping automated and manual versions of its biphasic external defibrillator this summer, backed by results from a company-sponsored clinical study of the device in treating atrial fibrillation.